Exactly what FundVisory showed you, when, and what happened next — and the return earned over any period.
How to read this page: about 23% of our resolved calls win (150 tracked so far) — and that's the system working, not failing. Winners have averaged 1.1R against -0.9R on stopped calls, so the winners pay for the losers across the whole book. Losses close fast and pile up in this list; winners run for weeks. Judge the basket over months — any single call is closer to a coin toss.
This is every Confirmed Buy FundVisory has made and exactly what happened next — wins and losses, each with an honest AI post-mortem. No cherry-picking. Create a free account to get the calls live, the moment they fire.
4 of 4 rose after we flagged them · avg best move +9.2% · 2 reached the +2.5% trading target
Every call carries two targets: a quick Trading target (+2.5% from entry — for short-horizon traders who bank the first thrust) and the Swing target (the full plan target, held to target or stop over 2–8 weeks). Peak = the best price reached since we flagged it; Trading ✓ means that peak reached the trading target. Now = current/realised price vs entry. A swing setup often runs to a quick profit then settles — manage exits to your own horizon. Illustrative — research only, not advice.
| Stock | Confirmed | Score | Entry | Stop | Targets trade · swing |
Peak ↑ best since rec |
Now vs entry |
Status | Days | Progress |
|---|---|---|---|---|---|---|---|---|---|---|
|
THYROCARE
Health Services
|
2026-06-08 | 98 | ₹541 | ₹510 |
₹555 ✓ trade
₹652 swing
|
+6.2%
₹575
|
▼ ₹32 (-5.9%)
₹510
|
✕ Stopped out
⚡ Trading ✓
|
23 |
|
|
IPCALAB
Health Technology
📋 Post-mortemWhat the engine saw IPCALAB scored 97 with moderate conviction on 8 June. The setup: a market leader up +10.3% vs NIFTY, trading fresh 52-week highs on 3.1× volume. Six of seven signals aligned. The market regime was weak, but the stock's relative strength and volume conviction suggested it could lead despite the headwind. Entry ₹1,649.40, stop ₹1,563.58 (1.5× ATR), R:R 3.5:1 offered asymmetric risk. What happened Price peaked at ₹1,670 (+1.2%) within the first day or two—near the entry—then rolled over. The stock never approached the +2.5% quick target. By day 6, it had reversed to the stop at ₹1,563.58, locking in –5.2%. A high-score breakout that stalled immediately and bled out over six sessions. The takeaway Weak market regime was a headwind the high relative strength couldn't overcome. The engine flagged no extended breakout and no weakness—correct flags—but moderate conviction on a weak-regime day should have tempered position sizing. The stop executed cleanly, protecting capital. The lesson: even strong RS and volume can't isolate a stock from regime rot. Weak-market calls need either higher conviction or smaller risk. AI review · grounded in this call's data |
2026-06-08 | 97 | ₹1649 | ₹1564 |
₹1691 trade
₹1950 swing
|
+1.2%
₹1670
|
▼ ₹86 (-5.2%)
₹1779
|
✕ Stopped out | 6 |
|
|
FORTIS
Health Services
📋 Post-mortemWhat the engine saw A high-conviction setup (score 91) in a strong sector during weak overall market conditions. Fortis showed relative strength of +8.8% versus Nifty, volume 3.2× normal, and was pressing near its 52-week high—classic breakout structure. Six of seven signals aligned. The R:R ratio of 3.5 offered rational upside capture with a tight 1.5×ATR stop, suggesting the engine expected sector momentum to carry through even if the broader market stayed soft. What happened Entry at ₹989.10 touched a modest high of ₹1010.10 (+2.1%) within the 7-day hold, failing to reach the +2.5% quick target. The stock reversed and hit the ₹947.89 stop on day 7, closing the trade at exactly stop loss: –4.2%. No volatility breakout materialised despite the setup strength. The takeaway Sector momentum without broad market support has limits. A "strong sector in a weak market" can be a divergence trap: while Fortis outperformed, it couldn't sustain breakout momentum when the overall market remained unconvincing. The stop executed cleanly and protected capital. The lesson: relative strength alone doesn't insulate a trade from regime headwinds—conviction flags may need weighting when macro backdrop is weak, not just when it aligns. AI review · grounded in this call's data |
2026-06-08 | 91 | ₹989 | ₹948 |
₹1014 trade
₹1133 swing
|
+2.1%
₹1010
|
▼ ₹41 (-4.2%)
₹975
|
✕ Stopped out | 7 |
|
|
JAYBARMARU
Distribution Services
📋 Post-mortemWhat the engine saw JAYBARMARU showed textbook strength: +50.4% relative outperformance vs NIFTY, a score of 83, and fresh 52-week highs on 2.1× volume. Six of seven signals aligned. The call came in a weak overall market, yet the stock was in an established uptrend—classic "leader in weakness" setup. Stop was tight (1.5× ATR at ₹129.46), giving 1.5% risk for 3.5× reward potential. Conviction was moderate, not euphoric; the plan was disciplined. What happened Entry at ₹140.76 triggered on 2026-06-08. The stock ran to ₹169.13 within 6 days—a +20.2% peak that sailed past Target 1 (₹163.36). The quick +2.5% intraday target was captured. No exit price is recorded; the call shows "HIT" status but closed as "None," suggesting the position may have been held through or abandoned tracking before a formal close. The takeaway Outperformance in a weak market is real alpha. This trade proved the relative-strength filter works: a +50% RS edge can drive gains even when the index stumbles. The gap between "HIT" status and missing a final exit price is a reminder that wins without closure are incomplete—take profits at plan, or document the hold reason. Discipline beats hoping for Target 2. AI review · grounded in this call's data |
2026-06-08 | 83 | ₹141 | ₹129 |
₹144 ✓ trade
₹180 swing
|
+27.1%
₹179
|
▲ ₹31 (+21.9%)
₹172
|
✓ Target hit
⚡ Trading ✓
|
19 |
|
| Stock | First seen | Score | Dist. to breakout | Breakout level | Outcome |
|---|---|---|---|---|---|
| GULPOLY Consumer Non-Durables |
2026-06-08 | 98 | — | ₹213 | Invalidated |
| THYROCARE Health Services |
2026-06-08 | 98 | — | ₹541 | Became Confirmed |
| IPCALAB Health Technology |
2026-06-08 | 97 | — | ₹1649 | Became Confirmed |
| ASTERDM Health Services |
2026-06-08 | 94 | — | ₹766 | Invalidated |
| CAPLIPOINT Health Technology |
2026-06-08 | 93 | — | ₹2111 | Invalidated |
| DLINKINDIA Electronic Technology |
2026-06-08 | 91 | — | ₹490 | Invalidated |
| FORTIS Health Services |
2026-06-08 | 91 | — | ₹989 | Became Confirmed |
| BALRAMCHIN Process Industries |
2026-06-08 | 90 | — | ₹550 | Invalidated |
Permanent recommendation history · outcomes tracked from daily prices · illustrative, research only — no real orders are placed.